← Back to Search

Other

IMX-110 for Cancer

Phase 1 & 2
Waitlist Available
Research Sponsored by Immix Biopharma Australia Pty Ltd
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is designed to assess the safety and tolerability of a new drug, IMX-110, with the goal of finding the recommended dose for further study.

Who is the study for?
This trial is for adults over 18 with advanced solid tumors who have not responded to standard treatments. They should expect to live at least 3 months, be in a decent physical state (ECOG 0-2), and have good heart function and blood test results. Participants must use effective contraception and cannot join if pregnant, breastfeeding, or planning pregnancy soon.
What is being tested?
IMX-110 is being tested in patients with various types of advanced solid tumors. The study has two phases: Phase 1 determines the safest dose with acceptable side effects (dose escalation) and Phase 2a tests this dose further (dose expansion).
What are the potential side effects?
While specific side effects are not listed here, typical ones may include reactions at the injection site, fatigue, nausea, changes in blood counts or liver enzymes which will be closely monitored throughout the trial.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Maximum tolerated dose (MTD) of IMX-110 in patients with advanced solid tumors for evaluation in Phase 2a.
Recommended Phase 2 Dose (RP2D) of IMX-110 in patients with advanced solid tumors
Secondary study objectives
Duration of Response (DOR)
Overall Survival (OS)
Plasma concentrations of IMX-110
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Imx-110Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Immix Biopharma Australia Pty LtdLead Sponsor
~9 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top